Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
|
|
- Gertrude Stafford
- 7 years ago
- Views:
Transcription
1 Open Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Input Output* HealthCare 2.0 billion R&D staff: ~7,500 CropScience 0.8 billion R&D staff: ~4,400 MaterialScience 0.2 billion R&D staff: ~900 26% R&D budget 2012: 3.0 billion 8% 65% Around 40 projects in clinical development or approval procedure, including five products with peak sales potential of 5 billion in total Our integrated product pipeline in crop protection and seed technology contains over 30 projects with estimated launch dates , plus numerous seed varieties Other 27 million R&D staff: ~100 1% New products and applications across all business units; leading-edge process technology for world-scale plants. * As of February 2013 Page 2 1
2 Bayer HealthCare Pharmaceuticals Excellent progress with pipeline Xarelto TM Reduces thrombosis risk Cardiology Oncology Adempas TM Stivarga TM Xofigo TM Reduces pressure in lung arteria Inhibits multiple enzymes that cause tumor growth Acts specifically against bone metastases Innovative products: cardiovascular, cancer & eye diseases Ophthalmology EYLEA TM Inhibits formation of new blood vessels at the back of the eye Page 3 Increasing challenges in the Healthcare Market Aging Population Patients / Consumers gain more Influence Highly efficient healthcare industry Rising costs and pressure on healthcare industry manufacturers Increasing Value Requirements Find options to de-risk research and increase flexibility Understand needs and specifics of diseases prevalent in emerging markets Need to come up with breakthrough innovation From Emerging Markets to Growth Markets Improve molecular understanding of disease mechanisms, better models, patient stratification These challenges cannot be addressed by the healthcare industry alone: partnerships are a key component Page 4 2
3 Our partners value true collaborations with close interaction and exchange of expertise. What was valued and is important to our partners Impact on organizing the partnership Partners seek for Partner Collaborations on eye-level with close interaction, exchange of expertise and mutual benefit Clear strategy and long-term perspective generate added value for all involved parties complementary expertise Excellent collaboration partners Sharing of knowledge Feedback from our partners: Bayer Bayer has high scientific expertise and good partnership management Excellent internal Drug Discovery expertise Long-term, reliable partnership Good partner interaction High level of mutual trust which allows for in-depth sharing of knowledge. ¹ Page 5 ¹ Insights based on a survey conducted with 52 partners from Biotech (23), CROs (3), and Academia (26) in May/June An integrated partnering approach to generate added value for all parties is key to success. Innovative and tailored Partnering Models 1 Internal Organization and processes: We focus on excellence in alliance and partnership management Added Value 2 Tailored and innovative partnering models: We focus on-eye-level` partnerships Internal Organizational Structures and Processes People s skills, partnering culture and mindset 3 Appropriate Skill set and open culture: We foster an open culture and skills by trainings and open innovation concepts Partnering is part of our Global Drug Discovery organization as an integrated function: Global External Innovation & Alliances Page 6 3
4 Partnerships are an integrative part of Global Drug Discovery Global External Innovation & Alliances is part of BHC Global Drug Discovery Global External Innovation & Alliances focuses on: Development & management of strategic alliances & open innovation initiatives Research Policy and public funding Strategic Outsourcing VC Investments Local Hubs: Innovation Center China Science Hub US Science Hub Singapore San Francisco Boston Headquarter Berlin Beijing Singapore Global External Innovation & Alliances is responsible for research partnering activities of Bayer HealthCare Global Drug Discovery Page 7 ¹ Global Drug Discovery Bayer HealthCare s approach of flexible partnering models Within BHC Type Involvement Examples Joint labs Close interaction, shared labs DKFZ Strategic innovation partnership Consortia Multiple projects, close interaction Broad Institute, Evotec Innovative Med.Initiative Joint research Crowdsourcing Outsourcing Individual project Singapore Network G4T, G4L Wuxi Apptech Licensing Transition of assets LDC Dortmund Incubator Arm s length CoLaborator SF/Berlin Venture Investments High Tech Gründerfonds Strategic Alliances and Open Innovation approaches are key elements for Breakthrough Innovation Page 8 4
5 Novel partnership models: Strategic alliance Bayer Healthcare and the German Cancer Research Center Strategic Alliance and Joint Lab of Bayer, DKFZ and NCT Heidelberg German Cancer Research Center (DKFZ) is one of the largest biomedical oncology research centers in Europe First agreement signed in 2009, collaboration extended for another 5 years in 2014 Collaboration along the entire drug discovery and development value chain Novel risk and reward sharing approach to collaborate with joint financing (up to 30 mio EUR within the next 5 y) and project selection (currently 26 joint projects) Extension of partnership by joint laboratory for immunotherapies at the National Center for Tumor Diseases (NCT) in Heidelberg in 2013 Bench Bedside Page 9 BHC Open Innovation Family Grants4Targets Grants4Leads Grants4Apps CoLaborator BHC grants for targets/ biomarkers. Offers expertise, tools and technologies to help develop your ideas. BHC grants to assess small molecule leads which may lead to collaborations to explore such leads. BHC grants for innovative IT projects which may lead to new business models. Unique incubator for startup life-science companies aligning with Bayer s interests. San Francisco Berlin com com apps.com com Page 10 5
6 Novel type of partnering: Crowd Sourcing Challenge* to be solved defined by seeking institution (pharma company) Internet as communication platform Review Collaboration (industry and academia) to address challenges Solutions/ideas provided by scientific community * such as the search for novel targets, compounds or indications for known assets Source: Lessl et al., 2011, Nature Drug Discovery 10, Page 11 Crowd sourcing: Page 12 6
7 Novel Type of partnering our Grants4Targets Initiative Background Numerous targets exist, but are invisible for us The knowledge outside > inside Idea Join forces with academia and biotech start ups to translate innovative targets into drugs Provision of grants to evaluate and validate novel targets Grants 4 Targets Approach Easily accessible Internet site and submission tool Low bureaucratic burden for both partners Clear communication on needs what are we looking for? Fast processing of requests Target Discovery Lead Generation Lead Optimization Preclinical Clinical Submission Page 13 Grant types within G4T program Support Grants ( 5,000-10,000) to further advance research on targets that are at a very early stage of discovery; fixed grant approval letter; IP rights remain with the applicant Focus Grants ( 10, ,000) for more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug-discovery process; fixed grant approval letter; IP rights remain with the applicant 7
8 Visitors [-] Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug G4T is running for 5 years and has completed 10 rounds of applications 1027 applications received 133 grants approved (12% acceptance rate) Most of the ideas are novel to us 2% 24% 9% 7% 22% 38% Germany Europe w/o D USA Asia RoW 55% 11% 11% 7% 14% marketed ongoing BSP project under evaluation in-house terminated project no current project not applicable Lessl et al., Drug Discovery Today 2011, Vol 16, rounds of applications completed World-wide footprint Now attracting almost 3000 visitors / month 4000 Visitors per Month Month 15 Bayer is planning to open the CoLaborator in Berlin in May 2014 Key features 800 m 2 assigned lab and office space on Bayer HealthCare s campus in the heart of Berlin for up to 9 start-up companies A new home for startups in life sciences with ideas related to Bayer HealthCare s R&D strategy Proximity to Bayer HealthCare research and the vicinity to Berlin s science and startup community create an eco-system for innovative ideas. Page 16 8
9 VC investments to promote innovative start-ups in HealthCare Page 17 We apply the RESOLVE¹ model for professional Alliance Management incorporated in our research organization. Value of Relationship and Culture Focus on personal relationships: trust, respect Behave as real partners Create awareness and manage diversity Value communication Open communication and exchange of information, active conflict resolution Mutual feedback on performance Mutual Benefit and Added Value Enthusiasm / commitment Commitment at all levels Willingness to overcome resistance Share credit Strategic fit Identify match partners with complementary strengths / skills Complementary and transparent goals Learning capabilities Openness to learn from each other Value from cross-organizational learning Drivers / motivation of partners to be steered in common direction Professional operational management Well-defined processes Transparent governance Goal orientation, clear objectives Clear Agreements on IP publications and payments ¹ Lessl & Douglas: Wissenschaftsmanagement. (2) 2010, p Page 18 9
10 Collaborative Innovation is a key concept of our strategy Bayer HealthCare is committed to Innovation Science for a better Life Strategic Partnering on eye-level is an integral part of our Drug Discovery Strategy We strive for tailored partnering concepts generating added value for both parties An integrated partnering approach ensures pipeline impact and value generation for our patients Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 10
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationEnhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017
From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationAnalytic-Driven Quality Keys Success in Risk-Based Contracts. Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst
Analytic-Driven Quality Keys Success in Risk-Based Contracts March 2 nd, 2016 Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst Brian Rice, Vice President Network/ACO Integration,
More informationBayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
More informationInvestor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
More informationEmployee performance management in a global setting. Brenda Wilson
Employee performance management in a global setting Brenda Wilson Performance management overview What is performance management? Performance management is a CORE business process driven by business strategy,
More informationAbbott Diagnostics. Durable Growth Business
Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act
More informationHow To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
More informationOutsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation
More informationEquipping your Forecasting Toolkit to Account for Ongoing Changes
Equipping your Forecasting Toolkit to Account for Ongoing Changes Presented by: Roger Parlett Supply Chain Manager January 23, 2014 Overview Forecast Set-up Objectives of Creating a Forecast Identify Critical
More informationWE ENGINEER THE FUTURE INVESTOR PRESENTATION AUGUST, 2015
WE ENGINEER THE FUTURE INVESTOR PRESENTATION AUGUST, 2015 FIRST SENSOR COMPANY PROFILE First Sensor AG is one of the world's leading suppliers in the field of sensor systems. Our company develops and manufactures
More informationConsumer ID Theft Total Costs
Billions Consumer and Business Identity Theft Statistics Business identity (ID) theft is a growing crime and is a growing concern for state filing offices. Similar to consumer ID theft, after initially
More informationAshley Institute of Training Schedule of VET Tuition Fees 2015
Ashley Institute of Training Schedule of VET Fees Year of Study Group ID:DECE15G1 Total Course Fees $ 12,000 29-Aug- 17-Oct- 50 14-Sep- 0.167 blended various $2,000 CHC02 Best practice 24-Oct- 12-Dec-
More informationFY 2015 Schedule at a Glance
Coaching and Mentoring for Excellence Oct 21 23, 2014 $2,950 Residential Coaching and Mentoring for Excellence Apr 7 9, 2015 $2,400 Non-residential Coaching and Mentoring for Excellence May 27 29, 2015
More informationTransforming relationships Unleashing innovation
Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries
More informationQuest for Growth Results for Q3, January-March 2003
Quest for Growth Results for Q3, January-March 2003 1 Jan Keuppens joins Quest Management Investment Manager Quoted Portfolio of Quest for Growth Former technology analyst with AXA Investment Managers,
More informationBiotech Opportunities for Start-Up Firms in Japan and Asia
Biotech Opportunities for Start-Up Firms in Japan and Asia - Corporate VC s Perspective - Yoshitaka Yoneyama, Ph.D. President & CEO Astellas Venture Management LLC. April 25, 2006 About Astellas Pharma
More informationBayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationIndustry view: Managing complex research and innovation portfolios in today s innovation environment. Thomas Görgen
Industry view: Managing complex research and innovation portfolios in today s innovation environment Thomas Görgen 150 years Bayer Science For A Better Life Page 2 Taftie - Industry view Thomas Görgen
More informationAbout CREST R&D Grant
1 About CREST R&D Grant Philosophy Higher value Electrical & Electronics (E&E) economic sector can be achieved when R&D thrives in the ecosystem This can be accelerated by promoting collaborative research
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationProject Management. Dissemination and Exploitation Services in Horizon 2020
Project Management Dissemination and Exploitation Services in Horizon 2020 Ontwerp: Studio Edwin de Boer 2 Project Management Dissemination and Exploitation Services in Horizon 2020 ttopstart - Project
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference November 14, 2013 Safe Harbor Statement 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this
More informationDipl. Kfm. Mario Hose, CEO
GERMAN DAY AT PDAC 2015. Dipl. Kfm. Mario Hose, CEO Project Financing Through German Partners March 3, 2015, 4:55 5:55pm Deal drivers Three parameters are the foundation for a successful deal! 1. Management
More informationCENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR
JULY 2015 Area (RS-1) GSR GSR (LCS-1) Texarkana Incorporated July-15 $0.50690/Ccf $0.45450/Ccf $0.00000/Ccf $2.85090/MMBtu $17.52070/MMBtu Texarkana Unincorporated July-15 $0.56370/Ccf $0.26110/Ccf $1.66900/Ccf
More informationBayer Accelerates Clinical Development of Promising New Drug Candidates
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Accelerates Clinical Development of Promising New Drug Candidates Five
More informationNORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer
NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer putting ideas to work March 2007 Dr. Rob Whitehead Associate Director, Office of Technology Transfer March 2008 Research Extensive, Land-grant
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationSingapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study
JOINT PRESS RELEASE EMBARGO TILL 7 August 2007, 1130 HOURS Singapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study A Singapore team of physician
More informationApples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI
Apples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI Market balance for table apples in EU-27 1.000 tons 2009/10 2010/11 2011/12 2012/13f Market production 10.984 9.651 10.663
More informationNew Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
More informationClinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.
Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma
More informationBig Data An Opportunity or a Distraction? Signal or Noise?
Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28
More informationLife Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com
Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;
More informationMOBILE AD TRENDS 2015
MOBILE AD S 2015 INNERACTIVE KEY S Inneractive s mobile programmatic platform processes billions of ad requests daily from around the world. We are strong believers in leveraging our data in order to provide
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationClinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com
Clinical Trials In Singapore Dr Say-Beng Tan, Dr Eugene Fidelis Soh, and Dr Han-Chong Toh Introduction Clinical trials are the gold standard for the evaluation of new treatment strategies. New treatments
More informationJanssen Research & Development 3210 Merryfield Row San Diego, CA 92121
NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationRBC Insurance Fetes Online Auto/Home Insurance Growth
Case Studies, K. Harris Research Note 29 October 2002 RBC Insurance Fetes Online Auto/Home Insurance Growth RBC Insurance's e-business successes are generating greater than $3 million in premiums per month.
More informationBayer Technology Services
Bayer Technology Services Company Profile 2013 (updated 1-Mar-2014) Page 1 Facts & Figures Portfolio Page 2 Bayer Technology Services a Bayer Subsidiary Holding company Group Management Board Bayer AG
More informationOncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING
Oncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING Client opportunities CONTENTS About us...02 Readership...04 Driving qualified leads...05 Our Journals...08 Editorial Calendar...10 Rate
More informationEDI Services helps healthcare network streamline workflow, increase productivity, and improve revenue cycle management.
GE Healthcare Results summary 2008 2010 Reduced eligibility rejection rate from 2% to 0.8% Reduced overall rejection rate from 6.4% to 4% Reduced cost to collect from 8.3% to 6.3% Increased the number
More informationwww.pwc.com/us/assetmanagement US Asset Management Strategic Imperatives for Asset Managers May 2013
www.pwc.com/us/assetmanagement US Asset Management Strategic Imperatives for Asset Managers May 2013 Table of contents Executive summary 1 Macro trends 2 Rise and interconnectivity of the emerging markets
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationChildren's Hospital Boston - Strategic SWOT Analysis Review
Brochure More information from http://www.researchandmarkets.com/reports/1837823/ Description: Summary Children's Hospital Boston (Children s) is the pediatric medical center that provides a full range
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationTim Howkins, CEO. Steve Clutton, Finance Director
Tim Howkins, CEO Steve Clutton, Finance Director Highlights Revenue Revenue up 36% Earnings per share up 33% All parts of business contributed to growth Benefits of increased IT spend Proposed final dividend
More informationInvestor science conference call: American College of Cardiology 2015
Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationRIIO-T1 business plan submission London Tuesday 6 September 2011
RIIO-T1 business plan submission London Tuesday 6 September 2011 Cautionary statement This presentation contains certain statements that are neither reported financial results nor other historical information.
More informationNATIONAL CREDIT UNION SHARE INSURANCE FUND
NATIONAL CREDIT UNION SHARE INSURANCE FUND PRELIMINARY & UNAUDITED FINANCIAL HIGHLIGHTS RENDELL L. JONES CHIEF FINANCIAL OFFICER MANAGEMENT OVERVIEW Balance Sheet Other - Insurance and Guarantee Program
More informationCorporate Prospectus January 2015
Corporate Prospectus January 2015 1000 Morris Ave, STEM Bldg., Union, NJ 07083 Tel: (908) 737-1922 Fax: (908) 737-1924 www.ilsebio.com The Institute for Life Science Entrepreneurship (ILSE) is a regional
More informationIntegrated Business planning in
Integrated Business planning in Philips Consumer Lifestyle Eelco van den Akker Philips Consumer Lifestyle 10 februari 2010 IBM Forum, Amsterdam Agenda Philips Consumer Lifestyle Business Planning Demand
More informationS&OP Case Study Creating Value at O Neal Manufacturing Services. Anthony Zampello, CPIM, CIRM, CSCP Adjunct Faculty Bentley University
S&OP Case Study Creating Value at O Neal Manufacturing Services Anthony Zampello, CPIM, CIRM, CSCP Adjunct Faculty Bentley University Prepared by: Jamie Cochran, Strategic Business Applications Manager,
More informationHow To Understand The Third Platform Ct Market Transformation In Latin America
Latin America 4 Pillars of the Third Platform Continuous Information Series Value Proposition June 2014 International Data Corporation (IDC) is the premier global provider of market intelligence, advisory
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationBASF Venture Capital GmbH
BASF Venture Capital GmbH Investment Strategy for Nanotechnology and Advanced Materials EuroNanoForum Riga 2015 Disclaimer This presentation contains forward-looking statements under the US Private Securities
More informationMedium Term Management Plan Next 100 Transform to Grow
Medium Term Management Plan Conference in Tokyo (June 17, 2014) NIKON CORPORATION Forward-looking statements for earnings and other performance data contained herein are based on information currently
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More informationCraig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
More informationThe Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals
The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical
More informationEngaging Clinical Trial Sites:
WHITE PAPER Engaging Clinical Trial Sites: The Role of the Clinical Trial Liaison Author: MARTIN LEE, MD Vice President, Global Scientific Affairs PRA Health Sciences Key Customers in Clinical Research
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationMarieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014
Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration
More informationBioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover
The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge
More informationwww.pwc.com/bigdecisions Are you prepared to make the decisions that matter most? Decision making in retail
www.pwc.com/bigdecisions Are you prepared to make the decisions that matter most? Decision making in retail Results from PwC s Global Data & Analytics Survey 2014 retail Showrooming and mobile search.
More informationSpring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai
From Our CEO Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai Featured Story WuXi and PRA Form Joint Venture to Offer Clinical Research Services
More informationTaking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationIntroduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
More informationCAFIS REPORT 2015.10
CAFIS REPORT 2015.10 INDEX Message CAFIS Inbound 03-06 07-08 CAFIS Arch 09-10 CAFIS Brain 11-12 CAFIS Global 13-14 What We Do 15-16 About CAFIS 17-18 Services for Member Stores 19-34 Services for Card
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationPROJECTS SCHEDULING AND COST CONTROLS
Professional Development Day September 27th, 2014 PROJECTS SCHEDULING AND COST CONTROLS Why do we need to Control Time and Cost? Plans are nothing; Planning is everything. Dwight D. Eisenhower Back to
More informationIntercontinentalExchange. Credit Suisse Financial Services Forum February 7, 2008
IntercontinentalExchange Credit Suisse Financial Services Forum February 7, 2008 Forward-Looking Statements Forward-Looking Statements This presentation may contain forward-looking statements made pursuant
More informationA vaccine for rheumatoid arthritis
A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright
More informationEMR and ehr Together for patients and providers. ehealth Conference October 3-4, 2014
EMR and ehr Together for patients and providers ehealth Conference October 3-4, 2014 DISCLOSURES: Commercial Interests NONE Susan Antosh is CEO of ehealth Saskatchewan Vision: Empowering Patients, Enabling
More informationDetailed guidance for employers
April 2015 3 Detailed guidance for employers Appendix A: Pay reference periods This document accompanies: Detailed guidance no. 3 Assessing the workforce Pay reference period calendars where the definition
More informationAPAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015
APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical
More informationFinancial Results. for FY 2010 ended March 2011. ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.
Financial Results for FY 2010 ended March 2011 ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.jp May 24, 2011 TRANS GENIC INC. Note: This material includes forward-looking
More informationMeeting Priorities of Biotech & Small Pharma Companies
Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,
More informationThe Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder
The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system
More informationEven we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
More informationProduct Development Partnerships (PDPs): Overview
Product Development Partnerships (PDPs): Overview Product Development Boot Camp 6 November 2015 Dr. Ryan Wiley President Shift Health is a healthcare strategy consultancy devoted exclusively to healthcare
More informationNHS BLOOD AND TRANSPLANT MARCH 2009 RESPONDING EFFECTIVELY TO BLOOD DONOR FEEDBACK
09/26 NHS BLOOD AND TRANSPLANT MARCH 2009 RESPONDING EFFECTIVELY TO BLOOD DONOR FEEDBACK EXECUTIVE SUMMARY From April 2009 an NHS wide common approach to complaint handling comes in to effect. This provides
More informationCase Study: Sales to Trial to Marketing Life Cycle
Case Study: Sales to Trial to Marketing Life Cycle Joanne White VP of Clinical Development Chitra Sundaram Assoc. Director- Enterprise Data Warehouse PAREXEL International, LLC Over $1 Billion in Annual
More informationMedical Billing and the Advantages of a Novelized Pharmaceutical Program
FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported
More informationWEATHERHEAD EXECUTIVE EDUCATION COURSE CATALOG
2016 WEATHERHEAD EXECUTIVE EDUCATION COURSE CATALOG APPRECIATIVE INQUIRY COMMUNICATION AND PROFESSIONAL SKILLS EMOTIONAL INTELLIGENCE FINANCIAL DECISION MAKING DESIGNING INNOVATION AND STRATEGY MANAGING
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015
2015-2016 SPECIAL TERM ACADEMIC CALENDAR For Scranton Education Online (SEOL), Masters of Business Administration Online, Masters of Accountancy Online, Health Administration Online, Health Informatics
More information